Landmark Bio has entered into a pivotal strategic manufacturing agreement with Galapagos NV, signaling a notable advance in the field of genomic medicines. This multi-year agreement positions Landmark Bio to produce clinical trial batches for Galapagos’ CAR T-cell therapies, with an emphasis on hematology-oncology, within the biotech hub of the Boston metropolitan area. Accelerating CAR-T […]
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission (EC) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. The approval of the once-daily, oral, JAK1 inhibitor is rheumatoid arthritis patients who showed inadequate response […]
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive global development and marketing rights for the atopic dermatitis drug, MOR106. This deal, potentially worth up to $1.1 billion, underscores Novartis’ commitment to advancing care in immuno-dermatology. Under the terms […]